O	0	1	A
O	2	7	phase
O	8	11	III
O	12	17	study
O	18	27	comparing
B-intervention	28	31	SB3
I-intervention	32	33	(
I-intervention	33	34	a
I-intervention	35	43	proposed
I-intervention	44	55	trastuzumab
I-intervention	56	66	biosimilar
I-intervention	66	67	)
O	68	71	and
B-control	72	83	trastuzumab
I-control	84	93	reference
O	94	101	product
O	102	104	in
O	105	109	HER2
O	109	110	-
O	110	118	positive
O	119	124	early
O	125	131	breast
O	132	138	cancer
O	139	146	treated
O	147	151	with
O	152	163	neoadjuvant
O	163	164	-
O	164	172	adjuvant
O	173	182	treatment
O	182	183	:
O	184	189	Final
O	190	196	safety
O	196	197	,
O	198	212	immunogenicity
O	213	216	and
O	217	225	survival
O	226	233	results
O	233	234	.

O	235	238	The
O	239	249	equivalent
O	250	258	efficacy
O	259	266	between
O	267	270	SB3
O	270	271	,
O	272	273	a
O	274	282	proposed
O	283	294	trastuzumab
O	295	305	biosimilar
O	305	306	,
O	307	310	and
O	311	314	the
O	315	326	trastuzumab
O	327	336	reference
O	337	344	product
O	345	346	(
O	346	349	TRZ
O	349	350	)
O	351	353	in
O	354	359	terms
O	360	362	of
O	363	366	the
O	367	373	breast
O	374	384	pathologic
O	385	393	complete
O	394	402	response
O	403	407	rate
O	408	413	after
O	414	425	neoadjuvant
O	426	433	therapy
O	434	436	in
B-eligibility	437	445	patients
I-eligibility	446	450	with
I-eligibility	451	456	early
I-eligibility	457	459	or
I-eligibility	460	467	locally
I-eligibility	468	476	advanced
I-eligibility	477	482	human
I-eligibility	483	492	epidermal
I-eligibility	493	499	growth
I-eligibility	500	506	factor
I-eligibility	507	515	receptor
I-eligibility	516	517	2
I-eligibility	517	518	-
I-eligibility	518	526	positive
I-eligibility	527	533	breast
I-eligibility	534	540	cancer
O	541	544	was
O	545	557	demonstrated
O	558	560	in
O	561	564	the
O	565	573	previous
O	574	580	report
O	580	581	.

O	582	586	Here
O	586	587	,
O	588	590	we
O	591	597	report
O	598	601	the
O	602	607	final
O	608	614	safety
O	614	615	,
O	616	630	immunogenicity
O	631	634	and
O	635	643	survival
O	644	651	results
O	652	657	after
O	658	669	neoadjuvant
O	669	670	-
O	670	678	adjuvant
O	679	688	treatment
O	688	689	.

O	690	698	Patients
O	699	703	were
O	704	714	randomised
O	715	716	1
O	716	717	:
O	717	718	1
O	719	721	to
O	722	729	receive
O	730	741	neoadjuvant
O	742	745	SB3
O	746	748	or
O	749	752	TRZ
O	753	756	for
O	757	758	8
O	759	765	cycles
O	766	778	concurrently
O	779	783	with
O	784	796	chemotherapy
O	797	798	(
O	798	799	4
O	800	806	cycles
O	807	809	of
O	810	819	docetaxel
O	820	828	followed
O	829	831	by
O	832	833	4
O	834	840	cycles
O	841	843	of
O	844	845	5
O	845	846	-
O	846	858	fluorouracil
O	858	859	/
O	859	869	epirubicin
O	869	870	/
O	870	886	cyclophosphamide
O	886	887	)
O	887	888	.

O	889	897	Patients
O	898	902	then
O	903	912	underwent
O	913	920	surgery
O	920	921	,
O	922	930	followed
O	931	933	by
O	934	936	10
O	937	943	cycles
O	944	946	of
O	947	955	adjuvant
O	956	959	SB3
O	960	962	or
O	963	966	TRZ
O	967	969	as
O	970	980	randomised
O	980	981	.

O	982	985	End
O	985	986	-
O	986	992	points
O	993	1001	included
B-outcome-Measure	1002	1008	safety
O	1008	1009	,
B-outcome-Measure	1010	1024	immunogenicity
O	1024	1025	,
B-outcome-Measure	1026	1031	event
I-outcome-Measure	1031	1032	-
I-outcome-Measure	1032	1036	free
I-outcome-Measure	1037	1045	survival
I-outcome-Measure	1046	1047	(
I-outcome-Measure	1047	1050	EFS
I-outcome-Measure	1050	1051	)
O	1052	1055	and
B-outcome-Measure	1056	1063	overall
I-outcome-Measure	1064	1072	survival
O	1073	1080	through
O	1081	1084	the
O	1085	1093	adjuvant
O	1094	1100	period
O	1100	1101	.

O	1102	1104	Of
B-total-participants	1105	1108	875
O	1109	1117	patients
O	1118	1128	randomised
O	1128	1129	,
B-total-participants	1130	1133	764
O	1134	1135	(
O	1135	1138	SB3
O	1138	1139	,
O	1140	1141	n
O	1142	1143	=
B-intervention-participants	1144	1147	380
O	1147	1148	;
O	1149	1152	TRZ
O	1152	1153	,
O	1154	1155	n
O	1156	1157	=
B-control-participants	1158	1161	384
O	1161	1162	)
O	1163	1172	completed
O	1173	1176	the
O	1177	1182	study
O	1182	1183	.

O	1184	1187	The
O	1188	1194	median
O	1195	1201	follow
O	1201	1202	-
O	1202	1204	up
O	1205	1213	duration
O	1214	1217	was
O	1218	1221	437
O	1222	1226	days
O	1227	1229	in
O	1230	1233	the
O	1234	1237	SB3
O	1238	1243	group
O	1244	1247	and
O	1248	1251	438
O	1252	1256	days
O	1257	1259	in
O	1260	1263	the
O	1264	1267	TRZ
O	1268	1273	group
O	1273	1274	.

O	1275	1278	The
B-outcome	1279	1288	incidence
I-outcome	1289	1291	of
I-outcome	1292	1301	treatment
I-outcome	1301	1302	-
I-outcome	1302	1310	emergent
I-outcome	1311	1318	adverse
I-outcome	1319	1325	events
O	1326	1329	was
O	1330	1340	comparable
O	1341	1348	between
O	1349	1355	groups
O	1356	1357	(
O	1357	1360	SB3
O	1360	1361	,
B-iv-bin-percent	1362	1364	97
I-iv-bin-percent	1364	1365	.
I-iv-bin-percent	1365	1366	5
I-iv-bin-percent	1366	1367	%
O	1367	1368	;
O	1369	1372	TRZ
O	1372	1373	,
B-cv-bin-percent	1374	1376	96
I-cv-bin-percent	1376	1377	.
I-cv-bin-percent	1377	1378	1
I-cv-bin-percent	1378	1379	%
O	1379	1380	)
O	1381	1387	during
O	1388	1391	the
O	1392	1399	overall
O	1400	1405	study
O	1406	1412	period
O	1412	1413	.

O	1414	1416	Up
O	1417	1419	to
O	1420	1423	the
O	1424	1427	end
O	1428	1430	of
O	1431	1436	study
O	1436	1437	,
O	1438	1441	the
B-outcome	1442	1449	overall
I-outcome	1450	1459	incidence
I-outcome	1460	1462	of
I-outcome	1463	1471	antidrug
I-outcome	1472	1480	antibody
O	1481	1484	was
O	1485	1488	low
O	1489	1491	in
O	1492	1496	both
O	1497	1506	treatment
O	1507	1513	groups
O	1514	1515	(
B-iv-bin-abs	1515	1516	3
O	1517	1525	patients
O	1526	1530	each
O	1530	1531	)
O	1531	1532	.

B-outcome	1533	1536	EFS
O	1537	1540	was
O	1541	1551	comparable
O	1552	1559	between
O	1560	1566	groups
O	1567	1571	with
O	1572	1573	a
O	1574	1580	hazard
O	1581	1586	ratio
O	1587	1588	(
O	1588	1591	SB3
O	1591	1592	/
O	1592	1595	TRZ
O	1595	1596	)
O	1597	1599	of
O	1600	1601	0
O	1601	1602	.
O	1602	1604	94
O	1605	1606	(
O	1606	1608	95
O	1608	1609	%
O	1610	1620	confidence
O	1621	1629	interval
O	1629	1630	,
O	1631	1632	0
O	1632	1633	.
O	1633	1635	59
O	1635	1636	-
O	1636	1637	1
O	1637	1638	.
O	1638	1640	51
O	1640	1641	)
O	1642	1645	and
B-outcome	1646	1649	EFS
I-outcome	1650	1655	rates
I-outcome	1656	1658	at
I-outcome	1659	1661	12
I-outcome	1662	1668	months
O	1669	1671	of
B-iv-bin-percent	1672	1674	93
I-iv-bin-percent	1674	1675	.
I-iv-bin-percent	1675	1676	7
I-iv-bin-percent	1676	1677	%
O	1678	1681	for
O	1682	1685	SB3
O	1686	1689	and
B-cv-bin-percent	1690	1692	93
I-cv-bin-percent	1692	1693	.
I-cv-bin-percent	1693	1694	4
I-cv-bin-percent	1694	1695	%
O	1696	1699	for
O	1700	1703	TRZ
O	1703	1704	.

O	1705	1710	Final
O	1711	1717	safety
O	1717	1718	,
O	1719	1733	immunogenicity
O	1734	1737	and
O	1738	1746	survival
O	1747	1754	results
O	1755	1757	of
O	1758	1762	this
O	1763	1768	study
O	1769	1776	further
O	1777	1784	support
O	1785	1788	the
O	1789	1802	biosimilarity
O	1803	1814	established
O	1815	1822	between
O	1823	1826	SB3
O	1827	1830	and
O	1831	1834	TRZ
O	1834	1835	.

O	1836	1850	ClinicalTrials
O	1850	1851	.
O	1852	1855	gov
O	1856	1857	(
O	1857	1868	NCT02149524
O	1868	1869	)
O	1869	1870	;
O	1871	1878	EudraCT
O	1879	1880	(
O	1880	1884	2013
O	1884	1885	-
O	1885	1891	004172
O	1891	1892	-
O	1892	1894	35
O	1894	1895	)
O	1895	1896	.
